All In Biotech

Drug Trial Radar · NCT03629756

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jul 24, 2018

Primary completion

Aug 18, 2021

Study completion Sep 3, 2021

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.

Conditions

  • Non-small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Bladder Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Merkel Cell Carcinoma
  • GastroEsophageal Cancer
  • Renal Cell Carcinoma
  • Castration-resistant Prostate Cancer

Interventions

  • EtrumadenantDrug

    Etrumadenant is an A2aR and A2bR antagonist.

  • ZimberelimabDrug

    Zimberelimab is a fully human anti-PD-1 monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with Adverse EventsTime frame: From first dose date to 90 days after the last dose (approximately 3 years)
  2. Percentage of participants who experience a Dose Limiting ToxicityTime frame: From first study treatment administration through Day 28

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Scottsdale Healthcare Hospitals dba HonorHealth

    Scottsdale, Arizona

  • University of California, Los Angeles

    Los Angeles, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • Rocky Mountain Cancer Centers (Midtown)

    Denver, Colorado

  • University of Michigan

    Ann Arbor, Michigan

  • QUEST Research Institute

    Royal Oak, Michigan

  • Carolina BioOncology Institute

    Huntersville, North Carolina

  • Prisma Health

    Greenville, South Carolina

  • Texas Oncology, P.A. - Fort Worth Cancer Center

    Fort Worth, Texas

  • Texas Oncology, P.A. - San Antonio Medical Center

    San Antonio, Texas

  • Texas Oncology, P.A. - Tyler

    Tyler, Texas

  • Medical Oncology Associates dba Summit Cancer Centers

    Spokane, Washington

  • Cabrini Health Limited

    Malvern, Australia

  • St. George Private Hospital

    Kogarah, New South Wales, Australia

  • Gallipoli Medical Research Foundation

    Greenslopes, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.